x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012073
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IF, Flow Cyt |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala472 of human Glut3 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SLC2A3 |
| UniProt No. | P11169 |
| Gene ID | 6515 |
| Gene Description | Glucose transporter 3 has a higher affinity for glucose than the ubiquitous glucose transporter Glut1. In the normal brain, Glut3 expression is limited to neurons, whereas Glut1 is expressed in both neurons and glia. Glioblastoma-derived brain tumor initiating cells express increased levels of Glut3, enabling their survival in the microenvironment deficient in glucose. In addition, Glut3 expression levels correlate with poor survival in brain tumors. Furthermore, integrin αvβ3 was shown to stimulate PAK4-YAP/TAZ signaling to upregulate Glut3 expression in glioblastoma cells. A subpopulation of glioblastoma was identified to be addicted to Glut3 and is highly sensitive to the disruption of integrin αvβ3-PAK4-YAP/TAZ signaling. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
